Payal Desai, MD, Formerly OSU Comprehensive Cancer Center
Articles by Payal Desai, MD, Formerly OSU Comprehensive Cancer Center
Sickle Cell Disease: Unmet Needs and Future Directions in Care
ByIfeyinwa (Ify) Osunkwo, MD, MPH, Atrium Health,Wally Smith, MD, Virginia Commonwealth University ,Nirmish Ramesh Shah, MD, Duke University,Payal Desai, MD, Formerly OSU Comprehensive Cancer Center Concluding their discussion on sickle cell disease management, expert panelists share key unmet needs and hopes for the future.
Educating Patients on Gene Therapy in Sickle Cell Disease
ByIfeyinwa (Ify) Osunkwo, MD, MPH, Atrium Health,Wally Smith, MD, Virginia Commonwealth University ,Nirmish Ramesh Shah, MD, Duke University,Payal Desai, MD, Formerly OSU Comprehensive Cancer Center Shared insight on patient education surrounding gene therapy in sickle cell disease and common misconceptions about this approach.
Understanding the Risk-Benefit Ratio of Gene Therapy in SCD
ByIfeyinwa (Ify) Osunkwo, MD, MPH, Atrium Health,Wally Smith, MD, Virginia Commonwealth University ,Nirmish Ramesh Shah, MD, Duke University,Payal Desai, MD, Formerly OSU Comprehensive Cancer Center An overview of gene therapy in sickle cell disease with a focus on the risk-benefit ratio observed in clinical trials and practice.
Factors in Selecting Disease-Modifying Therapy in SCD
ByIfeyinwa (Ify) Osunkwo, MD, MPH, Atrium Health,Wally Smith, MD, Virginia Commonwealth University ,Payal Desai, MD, Formerly OSU Comprehensive Cancer Center,Nirmish Ramesh Shah, MD, Duke University Panelists take a step back to consider when they might use certain disease-modifying therapy in the setting of sickle cell disease.
Sickle Cell Disease Management: Voxelotor Therapy
ByIfeyinwa (Ify) Osunkwo, MD, MPH, Atrium Health,Wally Smith, MD, Virginia Commonwealth University ,Nirmish Ramesh Shah, MD, Duke University,Payal Desai, MD, Formerly OSU Comprehensive Cancer Center Considerations for voxelotor’s unique mechanism of action and prospective use in patients with sickle cell disease.
Crizanlizumab Use in Sickle Cell Disease
ByIfeyinwa (Ify) Osunkwo, MD, MPH, Atrium Health,Wally Smith, MD, Virginia Commonwealth University ,Nirmish Ramesh Shah, MD, Duke University,Payal Desai, MD, Formerly OSU Comprehensive Cancer Center Panelists share their perspectives on the selection and use of crizanlizumab in certain patients with sickle cell disease.
Sickle Cell Disease Management: L-Glutamine Therapy
ByIfeyinwa (Ify) Osunkwo, MD, MPH, Atrium Health,Wally Smith, MD, Virginia Commonwealth University ,Nirmish Ramesh Shah, MD, Duke University,Payal Desai, MD, Formerly OSU Comprehensive Cancer Center Shared insight on L-glutamine therapy in sickle cell disease, with deference to observed efficacy and safety considerations.
Hydroxyurea Use in Sickle Cell Disease
ByIfeyinwa (Ify) Osunkwo, MD, MPH, Atrium Health,Wally Smith, MD, Virginia Commonwealth University ,Nirmish Ramesh Shah, MD, Duke University,Payal Desai, MD, Formerly OSU Comprehensive Cancer Center Expert perspectives on hydroxyurea as a staple therapy in the treatment armamentarium for sickle cell disease.
Treatment Goals and Guidelines in Sickle Cell Disease
ByIfeyinwa (Ify) Osunkwo, MD, MPH, Atrium Health,Wally Smith, MD, Virginia Commonwealth University ,Nirmish Ramesh Shah, MD, Duke University,Payal Desai, MD, Formerly OSU Comprehensive Cancer Center Focusing on disease-modifying therapeutics, expert panelists discuss foundational treatment goals and guidelines for sickle cell disease.
Patient Follow-up and Pain Management in Sickle Cell Disease
ByIfeyinwa (Ify) Osunkwo, MD, MPH, Atrium Health,Wally Smith, MD, Virginia Commonwealth University ,Nirmish Ramesh Shah, MD, Duke University,Payal Desai, MD, Formerly OSU Comprehensive Cancer Center Reflections on optimal approaches to patient follow-up, particularly regarding pain management and inherent risks in high-dose opioids.
Sickle Cell Disease: Applying Comprehensive Care to Patients
ByIfeyinwa (Ify) Osunkwo, MD, MPH, Atrium Health,Wally Smith, MD, Virginia Commonwealth University ,Nirmish Ramesh Shah, MD, Duke University,Payal Desai, MD, Formerly OSU Comprehensive Cancer Center A focused discussion on how comprehensive care is applied by multidisciplinary teams to improve the management of sickle cell disease.
Sickle Cell Disease: Overview of the Comprehensive Care Team
ByIfeyinwa (Ify) Osunkwo, MD, MPH, Atrium Health,Wally Smith, MD, Virginia Commonwealth University ,Nirmish Ramesh Shah, MD, Duke University,Payal Desai, MD, Formerly OSU Comprehensive Cancer Center A broad perspective on the value of multimodality care in the management of patients diagnosed with sickle cell disease.
Management of SCD: Educating Patients on Symptoms and Lifestyle Modification
ByIfeyinwa (Ify) Osunkwo, MD, MPH, Atrium Health,Wally Smith, MD, Virginia Commonwealth University ,Nirmish Ramesh Shah, MD, Duke University,Payal Desai, MD, Formerly OSU Comprehensive Cancer Center Wally Smith, MD, and Payal Desai, MD, spearhead a discussion on patient education surrounding sickle cell disease symptomology and lifestyle modifications.
Sickle Cell Disease and Newborn Screening
ByIfeyinwa (Ify) Osunkwo, MD, MPH, Atrium Health,Wally Smith, MD, Virginia Commonwealth University ,Nirmish Ramesh Shah, MD, Duke University,Payal Desai, MD, Formerly OSU Comprehensive Cancer Center Expert perspectives on the importance of newborn screening to impact mortality rates in sickle cell disease.
Sickle Cell Disease Global Prevalence
ByIfeyinwa (Ify) Osunkwo, MD, MPH, Atrium Health,Wally Smith, MD, Virginia Commonwealth University ,Nirmish Ramesh Shah, MD, Duke University,Payal Desai, MD, Formerly OSU Comprehensive Cancer Center Expert panelists reflect on the global prevalence of sickle cell disease, as well as general disease awareness.
Progression of SCD and Management Throughout a Patient’s Life
ByIfeyinwa (Ify) Osunkwo, MD, MPH, Atrium Health,Wally Smith, MD, Virginia Commonwealth University ,Nirmish Ramesh Shah, MD, Duke University,Payal Desai, MD, Formerly OSU Comprehensive Cancer Center Shared insight on how a patient’s life may progress following a diagnosis of sickle cell disease, along with considerations for pediatric versus adult management.
Overview of Sickle Cell Disease: Pathophysiology and Clinical Burden
ByIfeyinwa (Ify) Osunkwo, MD, MPH, Atrium Health,Wally Smith, MD, Virginia Commonwealth University ,Payal Desai, MD, Formerly OSU Comprehensive Cancer Center,Nirmish Ramesh Shah, MD, Duke University An overview on the pathophysiology of sickle cell disease and expert perspectives on the clinical (and psychosocial) burden it presents.
Progression of SCD and Management Throughout a Patient’s Life